CRLBF · Cresco Labs Inc.
Market Cap
$251.78M
Shares
371.85M
Volume · Oct 6
459.69K
Avg daily vol (3M)
505.4K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.64
Open$0.63
Day$0.63–0.66
52W close$0.63–1.92
Avg vol 30d664K
Short int1.0M · 0.3% float · 1.2d
Short vol44%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Up next
Next earnings call
Oct 22, 2026
Est · unconfirmed
· in 2 wks
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-9.5%
Year over year
Operating margin
-4.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.8%
Year over year · more shares
Price change (1Y)
-54.7%
Trailing year
Short interest
0.3%
Latest settlement · 1.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−13%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−34%
trailing
YTD return
−48%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 6 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.27% of float · ▼ -12.0% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score
29
low risk · 0–100
Fundamentals
Revenue growth
−9%
Y/Y
Gross margin
49%
contracting
EPS growth
−73%
Y/Y
Free cash flow
$37.8M
Balance sheet
$362.5M
net debt
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2026
Adjusted EBITDA margin
· third quarter
Non-GAAP
20%
Prior guidance
period ended
· from the Earnings Call filed May 8, 2026
Gross margins
· Q2
48% – 50%
Adjusted EBITDA margins
· Q2
21%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 6 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.27% of float · ▼ -12.0% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $2
vs 200-day avg -30%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRLBF
this stock
Cresco Labs Inc.
|
$251.78M | -48.0% | -9.5% | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +25.4% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.3% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
6
- % held
- 0.0%
- Reported
- 1 of 6
- Top holder
- ALBERT D MASON INC
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRLBF | -12.3% | -15.8% | -34.4% | +0.2% | -48.0% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -14.3% | -17.5% | -45.7% | -2.0% | -62.2% |